Hannah C Timmins1, Tiffany Li1, Terry Trinh2, Matthew C Kiernan1,3,4, Michelle Harrison5,6, Frances Boyle5,7, Michael Friedlander2,8, David Goldstein2,8, Susanna B Park1. 1. Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. 2. Prince of Wales Clinical School, University of New South Wales, Kensington, Australia. 3. Sydney Medical School, University of Sydney, Sydney, Australia. 4. Royal Prince Alfred Hospital, Camperdown, Australia. 5. Chris O'Brien Lifehouse, Sydney, Australia. 6. Department of Medical Oncology, Liverpool Hospital, Liverpool, Australia. 7. Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, South Brisbane, Australia. 8. Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia.
Abstract
BACKGROUND: Paclitaxel treatment produces significant peripheral neuropathy, but the time course of neuropathy development and outcomes are unclear. Dose reduction is the only strategy to prevent neurotoxicity, however, the impact of dose-reduction on neuropathy outcomes remains unknown. This study aimed to prospectively evaluated neuropathy development from weekly paclitaxel treatment and evaluate the impact of dose-reduction on post-treatment neuropathy outcomes. PATIENTS AND METHODS: Breast cancer patients receiving paclitaxel (80mg/m2 ) weekly for 12-weeks were prospectively assessed using patient reported (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity; FACTGOG-Ntx), clinical (Total Neuropathy Score clinical version; TNSc) and neurophysiological measures up to 12-months post completion. The impact of dose-reduction on post-treatment (3.6 ± 0.1 months) clinical and patient reported outcomes was evaluated in 105 weekly paclitaxel-treated patients. RESULTS: Significant neuropathy was present by 6-weeks across patient-reported, clinical, and objective neurophysiological assessments, increasing in prevalence and severity over the treatment course. Limited recovery occurred, with significant neuropathy being maintained up to 12 months (p < .05). Patients who received dose reduction had worse patient reported (FACT-GOG-Ntx: 40.2 ± .1.4) and clinical neuropathy outcomes (TNSc: 4.3 ± 0.4) compared to those who received the full dose (FACT-GOG-Ntx: 45.9 ± 0.9; TNSc: 3.3 ± 0.3, p < .05). Patients who ceased treatment early demonstrated the worse deficits (TNSc: 5.0 ± 0.6; FACT-GOG-Ntx: 37.3 ± 2.7) compared to those who received the complete dose (TNSc: 3.5 ± 0.3; FACT-GOG-Ntx: 45.3 ± 0.9, p < .05). CONCLUSION: Weekly paclitaxel produces symptomatic and objective neuropathy early in the treatment course which can persist. Dose reduction does not necessarily lead to more favorable neuropathy outcomes, with individual risk factors likely important in addition to cumulative dose. IMPLICATIONS FOR PRACTICE: Weekly paclitaxel schedules are extensively used in breast cancer. Patients may develop symptomatic and objective neuropathy early in the treatment course, with these individuals requiring closer monitoring. Furthermore, neuropathy is a long-term sequela that may impact quality of life and require appropriate supportive services. Results suggest that dose reduction does not necessarily lead to better neuropathy outcomes. Understanding schedule-specific toxicity and risk factors for neuropathy will be critical to determining individualized treatment strategies and improving quality of life in breast cancer survivors.
BACKGROUND:Paclitaxel treatment produces significant peripheral neuropathy, but the time course of neuropathy development and outcomes are unclear. Dose reduction is the only strategy to prevent neurotoxicity, however, the impact of dose-reduction on neuropathy outcomes remains unknown. This study aimed to prospectively evaluated neuropathy development from weekly paclitaxel treatment and evaluate the impact of dose-reduction on post-treatment neuropathy outcomes. PATIENTS AND METHODS: Breast cancerpatients receiving paclitaxel (80mg/m2 ) weekly for 12-weeks were prospectively assessed using patient reported (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity; FACTGOG-Ntx), clinical (Total Neuropathy Score clinical version; TNSc) and neurophysiological measures up to 12-months post completion. The impact of dose-reduction on post-treatment (3.6 ± 0.1 months) clinical and patient reported outcomes was evaluated in 105 weekly paclitaxel-treated patients. RESULTS: Significant neuropathy was present by 6-weeks across patient-reported, clinical, and objective neurophysiological assessments, increasing in prevalence and severity over the treatment course. Limited recovery occurred, with significant neuropathy being maintained up to 12 months (p < .05). Patients who received dose reduction had worse patient reported (FACT-GOG-Ntx: 40.2 ± .1.4) and clinical neuropathy outcomes (TNSc: 4.3 ± 0.4) compared to those who received the full dose (FACT-GOG-Ntx: 45.9 ± 0.9; TNSc: 3.3 ± 0.3, p < .05). Patients who ceased treatment early demonstrated the worse deficits (TNSc: 5.0 ± 0.6; FACT-GOG-Ntx: 37.3 ± 2.7) compared to those who received the complete dose (TNSc: 3.5 ± 0.3; FACT-GOG-Ntx: 45.3 ± 0.9, p < .05). CONCLUSION: Weekly paclitaxel produces symptomatic and objective neuropathy early in the treatment course which can persist. Dose reduction does not necessarily lead to more favorable neuropathy outcomes, with individual risk factors likely important in addition to cumulative dose. IMPLICATIONS FOR PRACTICE: Weekly paclitaxel schedules are extensively used in breast cancer. Patients may develop symptomatic and objective neuropathy early in the treatment course, with these individuals requiring closer monitoring. Furthermore, neuropathy is a long-term sequela that may impact quality of life and require appropriate supportive services. Results suggest that dose reduction does not necessarily lead to better neuropathy outcomes. Understanding schedule-specific toxicity and risk factors for neuropathy will be critical to determining individualized treatment strategies and improving quality of life in breast cancer survivors.
Authors: Hannah C Timmins; Tiffany Li; William Huynh; Matthew C Kiernan; Sally Baron-Hay; Frances Boyle; David Goldstein; Susanna B Park Journal: Clin Neurophysiol Date: 2020-04-02 Impact factor: 3.708
Authors: Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544
Authors: Andrew D Seidman; Donald Berry; Constance Cirrincione; Lyndsay Harris; Hyman Muss; P Kelly Marcom; Grandella Gipson; Harold Burstein; Diana Lake; Charles L Shapiro; Peter Ungaro; Larry Norton; Eric Winer; Clifford Hudis Journal: J Clin Oncol Date: 2008-04-01 Impact factor: 44.544
Authors: Jetter Robertson; Jeffrey Raizer; James S Hodges; William Gradishar; Jeffrey A Allen Journal: J Peripher Nerv Syst Date: 2018-05-11 Impact factor: 3.494
Authors: Ellen M Lavoie Smith; Robert Knoerl; James J Yang; Grace Kanzawa-Lee; Deborah Lee; Celia M Bridges Journal: Cancer Control Date: 2018 Jan-Mar Impact factor: 3.302
Authors: R Velasco; A A Argyriou; C Marco; S Mariotto; A Stradella; J Hernández; S Pernas; S Ferrari; J Bruna Journal: J Neurol Date: 2022-09-12 Impact factor: 6.682
Authors: Sebastian W Nielsen; Sanne Lindberg; Christina Halgaard Bruvik Ruhlmann; Lise Eckhoff; Jørn Herrstedt Journal: J Clin Med Date: 2022-03-27 Impact factor: 4.241
Authors: Natalia Mitin; Kirsten A Nyrop; Susan L Strum; Anne Knecht; Lisa A Carey; Katherine E Reeder-Hayes; E Claire Dees; Trevor A Jolly; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Erin A O'Hare; Hyman B Muss Journal: NPJ Breast Cancer Date: 2022-09-08